 NEW YORK, NY ACCESSWIRE October 1, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancers SITC 2021 36th Annual Meeting, taking place virtually November 10 - 14, 2021. Details of the presentations are outlined below. 